Perspective Therapeutics (CATX) Other Non-Current Liabilities (2011 - 2026)
Perspective Therapeutics (CATX) posted Other Non-Current Liabilities of $437000.0 for Q1 2026, up 13.21% sequentially from $386000.0 in Q4 2025, and up 201.38% YoY from $145000.0 in Q1 2025.
Perspective Therapeutics (CATX) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Perspective Therapeutics has reported Other Non-Current Liabilities for 16 years, with the latest figure at $437000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 201.38% year-over-year to $437000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $437000.0 (up 201.38% YoY) and the FY2025 annual result came in at $386000.0, up 601.82% from the prior year.
- Other Non-Current Liabilities advanced to $437000.0 in Q1 2026 per CATX's latest filing, from $386000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $668000.0 in Q3 2023 and troughed at $19000.0 in Q2 2024.
- A 5-year average of $418133.3 and a median of $437000.0 in 2026 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities tumbled 97.12% in 2024, then jumped 1394.74% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $657000.0 in 2022, then advanced by 1.67% to $668000.0 in 2023, then sank by 91.77% to $55000.0 in 2024, then jumped by 601.82% to $386000.0 in 2025, then grew by 13.21% to $437000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $437000.0, $386000.0, and $342000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Perspective Therapeutics | 396.34 Mn | 396.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 507,000.00 |
| Mar 31, 2026 | 437,000.00 |
| Dec 31, 2025 | 386,000.00 |
| Sep 30, 2025 | 342,000.00 |
| Jun 30, 2025 | 284,000.00 |
| Mar 31, 2025 | 145,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Sep 30, 2023 | 668,000.00 |
| Jun 30, 2023 | 659,000.00 |
| Mar 31, 2023 | 666,000.00 |
| Dec 31, 2022 | 657,000.00 |
| Sep 30, 2022 | 649,000.00 |
| Jun 30, 2022 | 640,000.00 |
| Mar 31, 2022 | 632,000.00 |
| Dec 31, 2021 | 624,000.00 |
| Sep 30, 2021 | 616,000.00 |
| Jun 30, 2021 | 608,000.00 |
| Mar 31, 2021 | 600,000.00 |